CZ2001629A3 - Nové formy hydrátů alendronátu sodného, způsob jejich výroby a farmaceutické kompozice na jejich bázi - Google Patents

Nové formy hydrátů alendronátu sodného, způsob jejich výroby a farmaceutické kompozice na jejich bázi Download PDF

Info

Publication number
CZ2001629A3
CZ2001629A3 CZ2001629A CZ2001629A CZ2001629A3 CZ 2001629 A3 CZ2001629 A3 CZ 2001629A3 CZ 2001629 A CZ2001629 A CZ 2001629A CZ 2001629 A CZ2001629 A CZ 2001629A CZ 2001629 A3 CZ2001629 A3 CZ 2001629A3
Authority
CZ
Czechia
Prior art keywords
compound
hydroxybutylidene
amino
sodium
equivalent
Prior art date
Application number
CZ2001629A
Other languages
Czech (cs)
English (en)
Inventor
Nina Finkelstein
Ramy Lidor-Hadas
Judith Aronhime
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of CZ2001629A3 publication Critical patent/CZ2001629A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CZ2001629A 1998-08-27 1999-08-27 Nové formy hydrátů alendronátu sodného, způsob jejich výroby a farmaceutické kompozice na jejich bázi CZ2001629A3 (cs)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9831398P 1998-08-27 1998-08-27
US12974399P 1999-04-16 1999-04-16
US14446199P 1999-07-19 1999-07-19

Publications (1)

Publication Number Publication Date
CZ2001629A3 true CZ2001629A3 (cs) 2001-08-15

Family

ID=27378576

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ2001629A CZ2001629A3 (cs) 1998-08-27 1999-08-27 Nové formy hydrátů alendronátu sodného, způsob jejich výroby a farmaceutické kompozice na jejich bázi

Country Status (30)

Country Link
US (2) US6281381B1 (https=)
EP (1) EP1107974B1 (https=)
JP (2) JP2002523514A (https=)
KR (2) KR20070034132A (https=)
AT (1) ATE334993T1 (https=)
AU (1) AU5698899A (https=)
BG (1) BG65329B1 (https=)
BR (1) BR9913472A (https=)
CA (1) CA2341459A1 (https=)
CZ (1) CZ2001629A3 (https=)
DE (1) DE69932620T2 (https=)
DK (1) DK1107974T3 (https=)
EA (1) EA002739B1 (https=)
EE (1) EE04552B1 (https=)
ES (1) ES2270613T3 (https=)
HR (1) HRP20010129A2 (https=)
HU (1) HUP0203078A3 (https=)
IL (1) IL141423A (https=)
IS (1) IS5864A (https=)
LT (1) LT4888B (https=)
LV (1) LV12720B (https=)
NO (1) NO20010957L (https=)
NZ (1) NZ510682A (https=)
PL (1) PL346347A1 (https=)
PT (1) PT1107974E (https=)
RO (1) RO122854B1 (https=)
SI (1) SI20581B (https=)
SK (1) SK2482001A3 (https=)
WO (1) WO2000012517A1 (https=)
YU (1) YU14701A (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406910B1 (fr) * 2001-07-16 2010-01-13 Universite Paris 13 Procedes de preparation de derives de bisphosphonates
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
CA2470495A1 (en) * 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
ITMI20020146A1 (it) * 2002-01-29 2003-07-29 Lyogen Ltd Alendronato monosodico amorfo e processo per la sua preparazione
AU2003226148A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050113343A1 (en) * 2003-10-14 2005-05-26 Pliva - Research And Development Ltd. Solid-state form of alendronate sodium and preparation thereof
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
DK2283825T3 (da) 2004-05-24 2022-06-27 Theramex Hq Uk Ltd Enterisk fast oral doseringsform af en bisfosfonat indeholdende et chelateringsmiddel
CZ296937B6 (cs) * 2004-09-02 2006-07-12 Zentiva, A. S Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
AU2005302500B2 (en) * 2004-10-29 2008-11-27 Sandoz Ag Processes for preparing glatiramer
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
CZ297262B6 (cs) * 2004-12-28 2006-10-11 Zentiva, A. S. Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové
US8003820B2 (en) * 2005-10-20 2011-08-23 Dr. Reddy's Laboratories Limited Process for preparing bisphosphonic acids
AR058168A1 (es) * 2005-11-07 2008-01-23 Merck & Co Inc Sintesis del alendronato de sodio trihidratado
NZ598071A (en) * 2006-10-27 2013-08-30 Signal Pharm Llc Uses of and pharmaceutical compositions comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
ES2392890T3 (es) * 2006-11-22 2012-12-14 Eisai R&D Management Co., Ltd. Sal sódica de un compuesto disacarídico, procedimiento para la producción de la misma y uso de la misma
US20090076144A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bazedoxifene
US20090118238A1 (en) * 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
WO2011054182A1 (zh) * 2009-11-03 2011-05-12 Liu Li 丹参酮ⅱa磺酸钠水合物及其制备方法和用途
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3016289A1 (de) 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4711800A (en) * 1985-06-06 1987-12-08 Divincenzo Maureen Needlecraft with metallic substrate
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5159108A (en) 1990-09-18 1992-10-27 Merck & Co., Inc. Process for preparing an antihypercalcemic agent
US5039819A (en) * 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
WO1996039149A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
CA2221844A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Disodium alendronate formulations

Also Published As

Publication number Publication date
LV12720B (en) 2002-02-20
EA200100184A1 (ru) 2001-10-22
US6281381B1 (en) 2001-08-28
RO122854B1 (ro) 2010-03-30
BR9913472A (pt) 2002-03-05
ATE334993T1 (de) 2006-08-15
SK2482001A3 (en) 2002-01-07
BG65329B1 (bg) 2008-02-29
NO20010957L (no) 2001-04-26
WO2000012517A1 (en) 2000-03-09
JP2009143955A (ja) 2009-07-02
LT2001016A (en) 2001-10-25
PL346347A1 (en) 2002-02-11
DK1107974T3 (da) 2006-10-30
EE04552B1 (et) 2005-10-17
NO20010957D0 (no) 2001-02-26
KR20070034132A (ko) 2007-03-27
BG105292A (en) 2001-12-29
KR20010079701A (ko) 2001-08-22
EP1107974A4 (en) 2001-09-26
HUP0203078A2 (hu) 2003-01-28
IL141423A0 (en) 2002-03-10
CA2341459A1 (en) 2000-03-09
DE69932620T2 (de) 2006-12-14
IS5864A (is) 2001-02-26
DE69932620D1 (de) 2006-09-14
LV12720A (lv) 2001-09-20
US6696601B2 (en) 2004-02-24
LT4888B (lt) 2002-02-25
WO2000012517A9 (en) 2000-07-13
AU5698899A (en) 2000-03-21
EP1107974A1 (en) 2001-06-20
HUP0203078A3 (en) 2005-01-28
IL141423A (en) 2005-09-25
NZ510682A (en) 2003-09-26
US20030065214A1 (en) 2003-04-03
HRP20010129A2 (en) 2005-04-30
SI20581B (sl) 2008-06-30
EA002739B1 (ru) 2002-08-29
PT1107974E (pt) 2006-10-31
YU14701A (sh) 2003-01-31
ES2270613T3 (es) 2007-04-01
EE200100126A (et) 2002-06-17
SI20581A (sl) 2001-12-31
EP1107974B1 (en) 2006-08-02
JP2002523514A (ja) 2002-07-30

Similar Documents

Publication Publication Date Title
CZ2001629A3 (cs) Nové formy hydrátů alendronátu sodného, způsob jejich výroby a farmaceutické kompozice na jejich bázi
WO2003086355A1 (en) Novel polymorphs and pseudopolymorphs of risedronate sodium
CZ2002404A3 (cs) Polymorfní formy torsemidu
US6963008B2 (en) Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
HUT64767A (en) Process for the production of disodium-4-chlorine-phenyl-thio-methylene-biphosphonate monohydrate and of pharmaceutical compositions containing it
US7618953B2 (en) Amorphous forms of risedronate monosodium
EP1702924A2 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
CZ20012942A3 (cs) Nový způsob přípravy alendronové kyseliny
AU2004202301B2 (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
MXPA01002017A (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
JPH0656857A (ja) アミジンおよび新規のアミジンを含む医薬組成物
US20090149427A1 (en) Pharmaceutically acceptable salts and hydrates of risedronic acid
EA008494B1 (ru) Кристаллическая форма мононатрия ризедроната
EP1923052A1 (en) Novel polymorphs and pseudopolymorphs of risedronate sodium
EP2180003A1 (en) Preparation of ibandronate trisodium
CZ297262B6 (cs) Trisodná sul kyseliny 4-amino-1-hydroxybutyliden-1,1-bisfosfonové